IMPACT Therapeutics, Inc (SEHK: 7630)
Salud · Biotecnología · CN
9,12 HK$
+8,64 % hoy · -78,2 % 1 año
IMPACT Therapeutics, Inc (SEHK: 7630) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 328,17 M $ y tiene 88 empleados.
En los últimos doce meses la acción ha bajado un 78,2 % y ha cotizado entre 7,87 y 47,98.
Tweenvest puntúa a IMPACT Therapeutics, Inc en cuatro factores: calidad 42/100, valor 70/100. Su punto más fuerte es valor.
Evolución de la cotización de 7630
Cifras clave
- Capitalización
- 328,17 M $
- Ingresos (últ. 12 m)
- 17,40 M $
- PER
- -9,27
- BPA
- -1,44
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 47,98 HK$
- Mínimo 52 semanas
- 7,87 HK$
- Volumen medio (3 m)
- —
- Acciones en circulación
- 282,46 M
- Empleados
- 88
- Próximos resultados
- —
Sobre IMPACT Therapeutics, Inc
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
- ISIN
- CNE100007LG4
- Fundada en
- 2009
- Cotiza desde
- 13 may 2026
- Bolsa
- The Stock Exchange of Hong Kong Ltd.
- Divisa
- HKD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Laekna, Inc.SEHK: 2105 | 338,09 M $ | 6,23 HK$ | -5,82 % |
| BioNote, Inc.KOSE: A377740 | 336,90 M $ | 4450,00 ₩ | -0,89 % |
| BioDlink International Company LimitedSEHK: 1875 | 333,92 M $ | 3,39 HK$ | +1,50 % |
| Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.SZSE: 300313 | 330,80 M $ | 9,20 CN¥ | -3,97 % |
| GC Corp.KOSE: A005250 | 325,65 M $ | 9580,00 ₩ | -1,44 % |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | 324,03 M $ | 5,98 $ | -0,99 % |
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | 320,09 M $ | 10,99 $ | -1,87 % |
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | 318,59 M $ | 3,12 $ | -1,58 % |